Healthcare >> CEO Interviews >> December 18, 2000
EDWARD S. ANDRLE is President and Chief Executive Officer of TERAMED,
Inc. He has had over 17 years of successful operating experience in
general management, marketing, business development, and venture capital
roles in the medical device field. Mr. Andrle joined TERAMED in January
1997 as President and CEO and lead the company from the product concept
stage through product development and into clinical trials. He
successfully directed the company through two rounds of financing and is
currently raising a third round. In 1996 he co-founded Myocor, Inc., a
start-up company focused on developing less-invasive therapies to treat
congestive heart failure. Myocor is currently engaged in worldwide
clinical trials of the Myosplint_, a revolutionary passive, implantable
device to treat congestive heart failure. Mr. Andrle spent five years at
SCIMED Life Systems as Vice President of Peripheral and Neuroradiology
and Vice President of Business Development. Mr. Andrle started the
Peripheral and Neuroradiology businesses at SCIMED, and his team
developed and launched over a dozen products that now account for over
$100 million in sales at Boston Scientific. Prior to that, he spent
three and a half years working with Institutional Venture Partners and
one of its portfolio companies, CEMAX. He also spent five years at
Baxter International in a variety of marketing positions in the renal
therapy business. Mr. Andrle is also an active investor in early-stage
medical device companies. He has invested in over 10 companies,
including TERAMED, Myocor, Intrabiotics, Protostar, ABS Medical, and
AbbeyMoor. Mr. Andrle holds an MBA degree from the Stanford Graduate
School of Business and a BS degree in Chemical Engineering from the
University of Notre Dame. Profile
Mr. Andrle: TERAMED develops, manufactures and markets endovascular
stent-graft systems to treat abdominal aortic aneurysms
